SEC Form 4 · accession 0001209191-17-008908

NEUROCRINE BIOSCIENCES INC · NBIX

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Director

Period of report

Feb 7, 2017

Accepted (ET)

Feb 8, 2017 · 7:38 pm EST

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0000914475

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Common Stock^F1	Feb 7, 2017	M	15,000	$3.40	A	45,048	D
Common Stock^F1	Feb 7, 2017	F	1,169	$43.60	D	43,879	D

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Non-Qualified Stock Option	$3.40	Feb 7, 2017	M	15,000	D	May 25, 2010	May 25, 2017	Common Stock	15,000	0	D

F1The share issuance reported on Table I reflects shares issued upon the exercise of options granted on May 25, 2010, which, if unexercised would have expired on May 25, 2017. The option exercises are reported on Table II. These option exercises were pursuant to a net issuance arrangement effected under the issuer's Equity Incentive Plan. The number of shares issued pursuant to the net issuance arrangement was calculated as follows: the option exercise price ($3.40) was subtracted from the February 7, 2017 market close price ($43.60), and this net amount ($40.20) was then multiplied by the number of options (15,000), with the resulting amount then divided by the market close price to result in a net issuance of 13,831 shares to the optionee. The 1,169 shares underlying the remaining portion of the options are not available for re-issuance, and no shares were sold into the market as a part of the exercise in connection with a net issuance program.